Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date.

Diabetes Metab Syndr Obes · 2019 · PMC6897065 · PMID 31819577

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

failed to reach statistical significanceno p-value reported

However, adverse events leading to early discontinuation of study drug were modestly greater in oral semaglutide (11%) than liraglutide (9%), a difference that failed to reach statistical significance.

also in 6,035 other papers

a positive trendno p-value reported

More importantly than the p-values, oral semaglutide showed a positive trend toward primary composite outcome reduction, similar to what was observed with the injectable form.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.